Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pain 11Neoplasms 8Cancer Pain 7Pain, Postoperative 2Pain, Intractable 2Lymphoma, Follicular 2Leukemia 2Waldenstrom Macroglobulinemia 1Vomiting 1Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Stomatitis 1Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 1Squamous Cell Carcinoma of Head and Neck 1Spinal Surgery 1Sleep Wake Disorders 1Signs and Symptoms 1Sezary Syndrome 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Postoperative Complications 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Pathologic Processes 1Pain Related to Cancer 1Opioid-Related Disorders 1Neurologic Manifestations 1

Interventions

Fentanyl 7Morphine 2Urinary Catheterization 1Ultracet 1Patient Positioning 1Passive Cutaneous Anaphylaxis 1Methadone 1Infusions, Intravenous 1Gastrostomy 1Administration, Sublingual 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breakthrough Pain × Methadone × Clear all
NCT00125294 2017-09-25

Sublingual Methadone for the Management of Cancer Breakthrough Pain

AHS Cancer Control Alberta

Phase 1 Completed
10 enrolled

Cancer Pain, Neoplasms, Pain, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡